睿知中国疾病研究地图
候选清单0

即将招募B 细胞急性淋巴细胞白血病早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07830238,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Diagnosed with B-ALL through MICM (cytological morphology, immunology, cytogenetics, and molecular genetics), and tested positive for CD19 by flow cytometry or immunohistochemistry.

    入选标准第 4 条

  3. Congestive heart failure with NYHA classification ≥ 3;

    排除标准第 16 条

  4. ≥ 2 lines of systemic treatment for recurrence or refractory;

    入选标准第 8 条

    Recurrent or refractory after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) (at least 6 months from the transplantation date to the administration date of SNC116);

    入选标准第 9 条

    Participants who have received targeted CD19 therapy (including monoclonal antibodies, bispecific antibodies, ADCs, CAR-NK, experimental treatments, etc.) must have CD19 expression still present after the last targeted CD19 therapy (if the CD19 expression is a quantitative result, the positive CD19 in the primitive cells must be > 90%).

    入选标准第 12 条

    During the screening period, serum pregnancy test results of fertile female participants must be negative (women who have undergone surgical sterilization or have been menopausal for at least 2 years are considered to have no fertility). Fertile female participants and male participants must use highly effective contraceptive methods throughout the entire clinical study period and within one year after the last study treatment; they must also commit not to donate eggs (oocytes, oocyte cells) / sperm for assisted reproduction within one year after the last study treatment.

    入选标准第 27 条

    Within the previous 2 years, had a malignant tumor that required treatment or had evidence of recurrence (excluding: fully cured non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, superficial bladder cancer, breast duct carcinoma in situ, thyroid cancer, and other localized carcinomas).

    排除标准第 4 条

    Had received the following drugs/treatments before SNC116 administration:

    排除标准第 26 条

    Received salvage treatment (including chemotherapy, TKIs for Ph-positive ALL, and blinatumomab, etc.) within 1 week or 5 half-lives (whichever is shorter);

    排除标准第 27 条

    Received CNS prophylactic treatment within 1 week;

    排除标准第 28 条

    Received treatment doses of corticosteroid drugs (prednisone > 20 mg/day or equivalent doses of other steroid hormones), except for local application or prevention of allergic reactions;

    排除标准第 29 条

    Received local palliative radiotherapy within 2 weeks;

    排除标准第 31 条

    Received large molecule drug treatment within 3 weeks;

    排除标准第 33 条

    Received lymphocytotoxic drugs such as fludarabine, chlorambucil, or cladribine within 3 months, or alemtuzumab or other lymphocytotoxic drugs within 6 months;

    排除标准第 40 条

    Received immune cell therapy such as CAR-T, CAR-NK, etc. within 3 months;

    排除标准第 41 条

    Previously received CD19 CAR-T cell therapy;

    排除标准第 43 条

  5. ECOG score 0 to 2.

    入选标准第 3 条

  6. Absolute neutrophil count (ANC) ≥ 0.5 × 10\^9/L;

    入选标准第 15 条

    Hemoglobin (Hb) ≥ 80 g/L;

    入选标准第 17 条

    Platelet count (PLT) ≥ 50 × 10\^9/L;

    入选标准第 18 条

    Serum ALT and AST ≤ 2.5 times the upper limit of normal;

    入选标准第 21 条

    Total bilirubin ≤ 1.5 times the upper limit of normal, except for Gilbert syndrome patients, whose total bilirubin must be ≤ 3.0 times the upper limit of normal;

    入选标准第 22 条

    Creatinine clearance rate (estimated by Cockcroft-Gault formula) ≥ 50 ml/min;

    入选标准第 23 条

    Participants receiving hematopoietic growth factor support therapy, including erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and platelet agonists (TPO), must have a 1-week interval between the last administration of growth factor support therapy and the screening period assessment; Participants receiving blood product transfusions must have a blood platelet assessment at least 1 week apart from the last platelet transfusion, and a blood hemoglobin assessment at least 1 week apart from the last red blood cell transfusion.

    入选标准第 26 条

  7. Had active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time of screening. Allowed participants to be enrolled if they had HBsAg positive and/or HBcAb positive but HBV-DNA negative, and/or HCVAb positive but HCV-RNA negative (if the research center reported reference value ranges, the normal upper limit of HBV-DNA and HCV-RNA detection was based on the detection values of each research center, and above the detection value limit was defined as "positive"; if the research center reported only "negative/positive", "positive" was based on the test report result).

    排除标准第 21 条

    Known positive serum HIV virus antibody or history of active HIV infection, and active syphilis patients.

    排除标准第 22 条

  8. Pregnant or lactating women;

    排除标准第 47 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07830238,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participants must meet all of the following inclusion criteria to be enrolled in this study:
  2. Age ≥ 18 years and ≤ 75 years, with no gender restrictions.
  3. ECOG score 0 to 2.
  4. Diagnosed with B-ALL through MICM (cytological morphology, immunology, cytogenetics, and molecular genetics), and tested positive for CD19 by flow cytometry or immunohistochemistry.
  5. Recurrence or refractory B-ALL is defined as:
  6. Early recurrence: Recurrence occurring within 12 months after the first complete remission;
  7. Primary refractory: Failure to achieve complete remission after two cycles of standardized chemotherapy;
  8. ≥ 2 lines of systemic treatment for recurrence or refractory;
  9. Recurrent or refractory after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) (at least 6 months from the transplantation date to the administration date of SNC116);
  10. For participants with Ph-positive disease, at least 2 different TKIs must have relapsed or been refractory, or the participant must be intolerant to TKI treatment, or have a TKI treatment contraindication, or be TKI-resistant (with T315i mutation or other resistance mechanisms).
  11. Bone marrow morphology shows > 5% of primitive cells.
  12. Participants who have received targeted CD19 therapy (including monoclonal antibodies, bispecific antibodies, ADCs, CAR-NK, experimental treatments, etc.) must have CD19 expression still present after the last targeted CD19 therapy (if the CD19 expression is a quantitative result, the positive CD19 in the primitive cells must be > 90%).
  13. Expected survival is greater than 3 months.
  14. Blood routine and lymphocyte subsets within 7 days before SNC116 administration meet the following requirements:
  15. Absolute neutrophil count (ANC) ≥ 0.5 × 10\^9/L;
  16. Absolute lymphocyte count (ALC) ≥ 0.5 × 10\^9/L;
  17. Hemoglobin (Hb) ≥ 80 g/L;
  18. Platelet count (PLT) ≥ 50 × 10\^9/L;
  19. CD3+ T cell absolute count ≥ 0.25 × 10\^9/L.
  20. Adequate liver, kidney, lung, and heart function, defined as:
  21. Serum ALT and AST ≤ 2.5 times the upper limit of normal;
  22. Total bilirubin ≤ 1.5 times the upper limit of normal, except for Gilbert syndrome patients, whose total bilirubin must be ≤ 3.0 times the upper limit of normal;
  23. Creatinine clearance rate (estimated by Cockcroft-Gault formula) ≥ 50 ml/min;
  24. Saturations of blood oxygen ≥ 92% under indoor ventilation conditions without clinical significance of pleural effusion;
  25. Left ventricular ejection fraction ≥ 45%; Echocardiography shows no clinical significance of pericardial effusion; ECG has no clinical significance of abnormal findings.
  26. Participants receiving hematopoietic growth factor support therapy, including erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and platelet agonists (TPO), must have a 1-week interval between the last administration of growth factor support therapy and the screening period assessment; Participants receiving blood product transfusions must have a blood platelet assessment at least 1 week apart from the last platelet transfusion, and a blood hemoglobin assessment at least 1 week apart from the last red blood cell transfusion.
  27. During the screening period, serum pregnancy test results of fertile female participants must be negative (women who have undergone surgical sterilization or have been menopausal for at least 2 years are considered to have no fertility). Fertile female participants and male participants must use highly effective contraceptive methods throughout the entire clinical study period and within one year after the last study treatment; they must also commit not to donate eggs (oocytes, oocyte cells) / sperm for assisted reproduction within one year after the last study treatment.
  28. Participants must agree not to donate blood, organs, sperm / semen, and/or eggs after SNC116 treatment for at least one year. Currently, there is no sufficient data to confirm when donating any tissue is safe; therefore, participants should not donate any tissue after receiving SNC116.
  29. Voluntarily participate in the clinical trial and sign the informed consent form.

排除标准:Exclusion Criteria:

  1. Participants who meet any of the following exclusion criteria will not be eligible to participate in this clinical study:
  2. Diagnosed with Burkitt leukemia/lymphoma or chronic myeloid leukemia with acute lymphocytic transformation according to the WHO classification.
  3. Recurrence with isolated extramedullary lesions.
  4. Within the previous 2 years, had a malignant tumor that required treatment or had evidence of recurrence (excluding: fully cured non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, superficial bladder cancer, breast duct carcinoma in situ, thyroid cancer, and other localized carcinomas).
  5. Known to have any allergic, hypersensitive, intolerant or contraindicated reaction to any component of SNC116 or the drugs used in the study (such as tocilizumab), or has previously experienced a severe allergic reaction.
  6. Had received any treatment using vesicular virus G glycoprotein pseudotyped virus.
  7. Had CNS diseases:
  8. (1) CNS-3; or with neurological changes CNS-2 (excluding those who have improved after treatment and are assessed by the investigator as meeting the criteria);
  9. (2) Had seizures, cerebrovascular accidents (ischemia/haemorrhage), dementia, mental disorders, cerebellar diseases, any autoimmune disease involving the CNS, post-reversible encephalopathy syndrome (PRES), or brain edema, etc. severe CNS disease conditions.
  10. Those with primary immunodeficiency or severe genetic diseases.
  11. Had clinically significant major cardiovascular diseases, including any of the following:
  12. Had myocardial infarction within 6 months before screening;
  13. Had unstable angina pectoris within 3 months before screening;
  14. Uncontrolled, clinically significant arrhythmias (such as persistent ventricular tachycardia, ventricular fibrillation, torsades de pointes);
  15. Mobitz II type II or III atrioventricular conduction block;
  16. Congestive heart failure with NYHA classification ≥ 3;
  17. Uncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg) or with hypertensive crisis or hypertensive encephalopathy;
  18. Had deep vein thrombosis or pulmonary embolism within 6 months before screening;
  19. Other cardiovascular diseases that were assessed by the investigator as significantly high-risk and not suitable for enrollment.
  20. Had ≥ 3 grade 3 gastrointestinal bleeding within the previous 1 month, a history of peptic ulcer disease, and the investigator assessed as having a risk of ≥ 3 grade 3 gastrointestinal bleeding or perforation (CTCAE 6.0).
  21. Had active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time of screening. Allowed participants to be enrolled if they had HBsAg positive and/or HBcAb positive but HBV-DNA negative, and/or HCVAb positive but HCV-RNA negative (if the research center reported reference value ranges, the normal upper limit of HBV-DNA and HCV-RNA detection was based on the detection values of each research center, and above the detection value limit was defined as "positive"; if the research center reported only "negative/positive", "positive" was based on the test report result).
  22. Known positive serum HIV virus antibody or history of active HIV infection, and active syphilis patients.
  23. Had active or latent Mycobacterium tuberculosis infection confirmed by clinical, imaging or laboratory examination during the screening period.
  24. Had an uncontrolled active infection that required intravenous use of antibiotics, antiviral or antifungal drugs, etc. within 7 days before SNC116 administration.
  25. At the time of screening, had a confirmed and requiring maintenance treatment systemic autoimmune disease or a confirmed systemic autoimmune disease in an active stage, except for: thyroid diseases assessed by the investigator as well-controlled.
  26. Had received the following drugs/treatments before SNC116 administration:
  27. Received salvage treatment (including chemotherapy, TKIs for Ph-positive ALL, and blinatumomab, etc.) within 1 week or 5 half-lives (whichever is shorter);
  28. Received CNS prophylactic treatment within 1 week;
  29. Received treatment doses of corticosteroid drugs (prednisone > 20 mg/day or equivalent doses of other steroid hormones), except for local application or prevention of allergic reactions;
  30. Received prophylactic treatment with short-acting oral antiretroviral drugs;
  31. Received local palliative radiotherapy within 2 weeks;
  32. Received traditional Chinese medicine with anti-tumor indications within 2 weeks;
  33. Received large molecule drug treatment within 3 weeks;
  34. Received experimental drugs/treatment (except for clear placebo-controlled groups);
  35. Experienced major surgery within 4 weeks;
  36. Received live vaccines within 4 weeks;
  37. Received immunosuppressants within 4 weeks;
  38. Used any drugs for treating GVHD (such as calcineurin inhibitors, methotrexate, mycophenolate mofetil, rapamycin, thalidomide, etc.) within 4 weeks (except for calcium channel blockers, methotrexate, mycophenolate mofetil, rapamycin, thalidomide, etc.);
  39. Received donor lymphocyte infusion (DLI) within 4 weeks;
  40. Received lymphocytotoxic drugs such as fludarabine, chlorambucil, or cladribine within 3 months, or alemtuzumab or other lymphocytotoxic drugs within 6 months;
  41. Received immune cell therapy such as CAR-T, CAR-NK, etc. within 3 months;
  42. At the time of screening, any adverse events related to previous anti-leukemia treatment that have not recovered to ≤ grade 1 or baseline level (CTCAE version 6.0) (except for alopecia, hematological toxicity related to the inclusion criteria 8, or other grade 2 adverse events that have been converted to chronic stable state by the investigator, such as alternative treatment for hypothyroidism);
  43. Previously received CD19 CAR-T cell therapy;
  44. Experienced grade 4 neurotoxicity or grade 4 cytokine release syndrome during T-cell redirected immunotherapy;
  45. Had any indwelling catheters or drainage tubes in the body (such as percutaneous nephrostomy tube, biliary drainage tube, or thoracic/abdominal/pericardial drainage catheter, etc.), except central venous catheterization and Ommaya reservoir;
  46. Had 2-4 grade acute graft-versus-host disease (GVHD) or moderate to severe chronic GVHD within 4 weeks before screening; or had acute or chronic GVHD that required systemic treatment within 4 weeks before screening;
  47. Pregnant or lactating women;
  48. Other situations that the investigator considers may affect the safety or study compliance of the participants and are not suitable for participation in the study.

引自 ClinicalTrials.gov, NCT07830238, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07830238,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07830238